Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2110183 with chemotherapy for platinum-resistant ovarian cancer
ISRCTN22893535Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of afuresertib in ovarian cancer and fallopian tube cancer (PFTC) (2 arms), sponsored by Imperial College London. Primary endpoints: Overall response, CA125 response and 3 more. Started Dec 2012; status: completed.
02
Drugs
afuresertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ISRCTN22893535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22893535.